Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results. "This is ...

STAAR Surgical Company beats earnings expectations. Reported EPS is $0.41, expectations were $0.19. Operator: Greetings and welcome to the STAAR Surgical Third Quarter 2024 Earnings Webcast. As a ...

Greetings and welcome to the STAAR Surgical Third Quarter 2024 Earnings Webcast. As a reminder, this event is being recorded today Wednesday, October 30th, 2024. During today's presentation ...

The FDA agreed that Sangamo could use data from its ongoing Phase I/II STAAR trial (NCT04046224) as a primary basis for accelerated approval of isaralgagene civaparvovec—specifically ...

The first catalyst which would be the release of intermediate eGFR slope data at 52 weeks from the phase 1/2 STAAR study in the 1st half of 2025. From there, if this endpoint goes well ...

About ¾ of all students in the district could perform below grade level on the spring STAAR test ... Some of the other initiatives include resources for all teachers and sending central office ...

In November 2023, Sangamo kicked off a strategic reprioritization initiative to focus its resources on its genomic editing and delivery technologies ... indicating in an investor note that Sangamo’s ...

The STAAR study enrolled male and female patients who are on ERT ... Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to our lack of ...

We’re sorry. The event that you are trying to access is no longer available. Please look at our current events London events or Cosford events. Please contact the London or Cosford team if you are ...